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Notch signaling is directed through RBPJ, the 
DNA-binding component of the pathway (Kovall 
and Hendrickson, 2004; Borggrefe and Oswald, 
2009). RBPJ is ubiquitously expressed and acts 
as a transcriptional repressor in the absence of 
active Notch (Hamaguchi et al., 1992; Bray, 
2006). Binding of active Notch to RBPJ results 
in expulsion of a histone deacetylase-containing 
corepressor complex and recruitment of his-
tone acetyltransferases to the Notch–RBPJ ter-
nary complex to facilitate chromatin remodeling 
and transcriptional activation (Borggrefe and 
Oswald, 2009). Increased expression of Notch1 
or its ligand Jagged1 is associated with poor sur-
vival in breast and other cancers (Reedijk et al., 
2005; Koch and Radtke, 2007). To evaluate the 
relevance of RBPJ in tumor promotion, we 
examined RBPJ mRNA and protein levels in 
primary human cancers and modeled RBPJ 
depletion in tumor xenograft studies.
RESULTS
RBPJ is frequently lost in human cancers
To determine whether altered RBPJ expression 
is associated with oncogenesis, we performed 
immunohistochemical staining of 264 human 
breast carcinoma cases. Immunostaining revealed 
lack of RBPJ protein in 15% (40/264) of cases, 
whereas nonmalignant breast tissue showed high 
levels of epithelial expression (Fig. 1 A). RBPJ 
loss did not correlate with hormone receptor or 
human epidermal growth factor receptor 2 status 
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Aberrant Notch activity is oncogenic in several malignancies, but it is unclear how expression 
or function of downstream elements in the Notch pathway affects tumor growth. Transcrip-
tional regulation by Notch is dependent on interaction with the DNA-binding transcriptional 
repressor, RBPJ, and consequent derepression or activation of associated gene promoters. We 
show here that RBPJ is frequently depleted in human tumors. Depletion of RBPJ in human 
cancer cell lines xenografted into immunodeficient mice resulted in activation of canonical 
Notch target genes, and accelerated tumor growth secondary to reduced cell death. Global 
analysis of activated regions of the genome, as defined by differential acetylation of histone 
H4 (H4ac), revealed that the cell death pathway was significantly dysregulated in RBPJ-
depleted tumors. Analysis of transcription factor binding data identified several transcrip-
tional activators that bind promoters with differential H4ac in RBPJ-depleted cells. 
Functional studies demonstrated that NF-B and MYC were essential for survival of RBPJ-
depleted cells. Thus, loss of RBPJ derepresses target gene promoters, allowing Notch- 
independent activation by alternate transcription factors that promote tumorigenesis.
© 2015 Kulic et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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Analysis of microarray data from a study in which tumors 
were classified by grade showed that RBPJ expression was 
preferentially reduced in higher-grade breast cancers (Fig. 1 E; 
Ginestier et al., 2006), suggesting that reduced RBPJ expres-
sion may be associated with more aggressive tumors. Of inter-
est, a significant negative correlation between expression of 
RBPJ and its canonical target gene, HEY2, was observed in 
the grade 3 subset (n = 39, R2 = 0.2, Pearson P = 0.003). 
A separate invasive lobular breast carcinoma dataset also showed 
(unpublished data). Examination of microarray data from in-
dependent studies confirmed significantly reduced RBPJ mRNA 
expression in breast cancers (Fig. 1 B; Yu et al., 2008). Using 
TCGA data (Network, 2012), we evaluated RBPJ copy loss 
and mRNA expression in invasive breast cancers. Genomic 
loss of RBPJ occurred in 33% (277/828) of cases, and this co-
incided with significantly reduced transcript levels (Fig. 1 C). 
Cases either with RBPJ homozygous deletion (HD; n = 7) 
and loss (n = 270) showed the lowest RBPJ expression (Fig. 1 D). 
Figure 1. RBPJ is frequently lost in human 
cancers. (A) Examples of RBPJ immunohisto-
chemical staining in benign breast tissue (n = 8) 
and breast cancer tissue microarray cores 
(RBPJ negative, n = 40; RBPJ positive,  
n = 224; bar, 200 µm). High power inset (bar = 
100 µm) of the RBPJ-negative tumor core  
shows positive staining in internal control 
cells in the tumor microenvironment. (B) RBPJ 
mRNA expression in breast tumors (n = 183) 
and adjacent normal breast tissue (n = 13; Yu 
et al., 2008). (C) Analysis of RBPJ expression 
and RBPJ genomic copy loss (n = 277) versus 
no loss (neutral, n = 551) in invasive breast 
cancers (TCGA data). (D) Data from C plotted 
by RBPJ copy number status; HD (n = 7), loss 
(n = 270), neutral (n = 489), and amplification 
(gain, n = 62). P < 0.0001 by Kruskal–Wallis 
followed by Dunn’s multiple comparisons 
post-test showed significant differences in all 
comparisons except between the HD versus 
loss group. (E) RBPJ mRNA expression in human 
breast cancers stratified by tumor grade; 
grade 1 (n = 4), grade 2 (n = 12), and grade 3 
(n = 39; Ginestier et al., 2006). (F) RBPJ mRNA 
expression in normal bronchial epithelium 
collected from healthy individuals (n = 67) 
versus non–small cell lung carcinoma (n = 111; 
Bild et al., 2006; Lockwood et al., 2010).  
(G) Analysis of lung cancers of mixed type with 
RBPJ genomic copy loss (n = 14) versus no 
loss (n = 30) with paired mRNA expression 
and aCGH data (Lockwood et al., 2008, 2010). 
(H) Analysis of lung cancers from G broken 
down into tumor subtypes; adenocarcinoma 
RBPJ genomic loss (n = 6) versus no loss (n = 19); 
squamous cell carcinoma RBPJ genomic loss 
(n = 8) versus no loss (n = 11; Lockwood  
et al., 2008, 2010). (I) Analysis of RBPJ mRNA 
expression and genomic copy number in TCGA 
lung cancer adenocarcinomas (RBPJ genomic 
loss [n = 15] versus no loss [n = 114]) and 
squamous cell carcinomas (RBPJ genomic loss 
[n = 77] versus no loss [n = 101]; Cerami  
et al., 2012; Lockwood et al., 2012; Gao et al., 
2013). (J) RBPJ copy number alteration evalu-
ated using aCGH across a panel of 215 cancer cell lines (CNS: central nervous system, HC: hematopoietic cell lines). At least one allele of RBPJ is lost at an 
overall frequency of 35% (also see Table S1). P-values were obtained using a Mann-Whitney test for B, C, and F–I and a Kruskal-Wallis one-way analysis 
of variance test for D and E. Data are presented as box-and-whisker plots. The bottom and top bars of the whisker indicate the 5th and 95th percentiles 
respectively with points outside the whiskers shown as individual dots. *, P < 0.05, **, P < 0.005, ***, P < 0.0001.
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RBPJ deficiency promotes tumor growth
To determine whether RBPJ depletion promotes tumor pro-
gression, we knocked down RBPJ in MDA-MB-231 human 
breast cancer cells and subcutaneously implanted the cells 
into immunodeficient mice (Fig. 2, A and B). Stable RBPJ 
knockdown using either of two independent short hairpin 
(sh) RNAs significantly increased MDA-MB-231 tumor 
growth compared with two independent control cell lines 
expressing distinct nonspecific shRNAs (Fig. 2, C and D). In 
contrast, expression of a mutant (mt)-RBPJ (MacKenzie et al., 
2004), which blocks Notch-driven transcription but permits 
endogenous RBPJ to bind DNA and retain repression, inhib-
ited MDA-MB-231 tumor growth similar to direct blockade 
of Notch (Fig. 2, E and F; Leong et al., 2007). Before tumor 
seeding, the mt-RBPJ transcript was expressed 5.5-fold above 
vector control cells but only 3.5-fold in excised endpoint tu-
mors (unpublished data). Modest overexpression of mt-RBPJ 
protein in endpoint tumors (Fig. 2 E) is likely due to prefer-
ential outgrowth of cells not expressing the construct. We 
confirmed increased tumor growth consequent to RBPJ loss in 
a Burkitt lymphoma cell line, DG75, in which RBPJ has been 
genetically ablated (Fig. 2, G–I; Maier et al., 2005). Thus, two 
independent methods demonstrate that RBPJ depletion pro-
motes tumor growth in various malignancies.
a negative correlation between RBPJ and HEY2 mRNA ex-
pression (n = 18, R2 = 0.4, Pearson P = 0.005; Rhodes et al., 
2004; Zhao et al., 2004).
We also evaluated RBPJ in non–small cell lung cancers (n = 
111) compared with normal bronchial epithelium from healthy 
individuals (n = 67) and observed reduced expression in tu-
mors (Fig. 1 F; Bild et al., 2006; Lockwood et al., 2010). Ge-
nomic loss of at least one copy of RBPJ was associated with 
significantly reduced transcript levels in primary lung tumors 
(Fig. 1 G; Lockwood et al., 2008; Lockwood et al., 2010). Clas-
sification of tumors in Fig. 1 G into subtypes showed that RBPJ 
copy number loss occurred more frequently in lung squamous 
cell carcinomas compared with adenocarcinomas, consistent with 
our analysis of TCGA lung tumor data (Fig. 1, H and I; Cerami 
et al., 2012; Lockwood et al., 2012; Gao et al., 2013).
Examination of 215 different tumor cell lines representing 
15 tumor types showed that deletion of at least one copy of 
RBPJ occurred in 35% of all cell lines (Fig. 1 J and Table S1). 
Oncomine analysis of additional cancer datasets revealed sig-
nificant RBPJ underexpression in tumor tissue relative to 
matched normal tissue, including colon, bladder, ovarian, and 
gastric cancers (Rhodes et al., 2004; unpublished data). In 
contrast to NOTCH1, our analysis supports that RBPJ ex-
pression is reduced in several tumor types.
Figure 2. RBPJ deficiency promotes  
tumor growth. (A and B) Analysis of MDA-
MB-231 tumors transduced with an RBPJ 
knockdown construct (shRBPJ) or a nonspe-
cific shRNA (shRandom). (A) Immunoblot of 
endpoint tumor lysates. (B) RBPJ immuno-
histochemistry (bar, 50 µm). (C) MDA-MB-231 
tumor growth after expression of shRBPJ  
(n = 16) compared with shRandom control  
(n = 22). (D) Depletion of RBPJ in MDA-MB-
231 tumors using an alternate RBPJ targeting 
construct (set2) and a different silencing con-
trol (shScrambled; n = 4 for each group).  
(E) Immunoblot analysis of endpoint MDA-
MB-231 tumor lysates transduced with LNCX 
empty vector or an mt RBPJ construct (LNC-
mt-RBPJ). (F) MDA-MB-231 tumor growth 
after expression of LNC-mt-RBPJ compared 
with the LNCX control (n = 8 for each group). 
(G and H) Analysis of parental or RBPJ/ 
DG75 Burkitt lymphoma tumors. (G) Immuno-
blot of endpoint tumor lysates. (H) RBPJ  
immunohistochemistry (bar, 50 µm). (I) DG75 
RBPJ/ tumor growth (n = 10) compared 
with parental DG75 tumors (n = 9). For C, F, 
and I, p-values were obtained using a Mann-
Whitney test and for D a one-way ANOVA. 
Data are presented as mean ± SEM. *, P < 0.05; 
**, P < 0.005; ***, P ≤ 0.0005.
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target gene expression is not solely an indicator of Notch re-
ceptor activity, as RBPJ depletion represents an alternate mech-
anism for promoting tumor growth and HEY expression.
To evaluate whether RBPJ loss produces a Notch-like gene 
signature, we identified genes differentially expressed in 10 
human T-ALL cell lines with Notch activating mutations treated 
with vehicle or a Notch inhibitor (Benjamini-Hochberg cor-
rected P ≤ 0.05; Margolin et al., 2009). 170 genes showing 
a change in response to the Notch inhibitor across all T-ALL 
lines were defined as Notch-regulated genes (Table S2). Based 
on this signature, we assigned a Notch signature score (see 
Materials and methods) for each of the 828 invasive breast 
cancers from the TCGA dataset (shown in Fig. 1 C) compar-
ing mean scores between samples with RBPJ loss to those 
without. Breast cancers with RBPJ loss had a significantly in-
creased Notch signature score compared with tumors with-
out RBPJ loss (Fig. 3 E). The breast cancer cases with RBPJ 
HD, copy loss, or copy gain had a significantly higher Notch 
signature score compared with samples with neutral RBPJ copy 
number (Fig. 3 F). These data imply that RBPJ activates a 
subset of Notch target genes.
RBPJ depletion causes epigenetic changes  
that correspond to promoter activity
To address how RBPJ loss leads to target gene activation, we 
first assessed whether another transcriptional activator binds 
RBPJ deficiency results in a Notch-like gene signature
Because RBPJ acts as a transcriptional repressor, depletion 
can result in induction of target genes (Raafat et al., 2009; 
Liefke et al., 2010; Meier-Stiegen et al., 2010). We confirmed 
that RBPJ knockdown in MDA-MB-231 xenografts caused 
significant up-regulation of well characterized target genes 
of the HEY gene family (Fig. 3 A). HES1, SNAIL1, and 
GUCY1A3, additional known Notch target genes (Sahlgren 
et al., 2008; Borggrefe and Oswald, 2009; Chang et al., 2011), 
along with MMP1 were also up-regulated in RBPJ-depleted 
tumors (Fig. 3 B). To determine whether Notch activity con-
tributes to transcriptional activation in the absence of RBPJ, 
we blocked activation of all Notch receptors in vitro using 
the -secretase inhibitor N-[N-(3,5-difluorophenacetyl)-l-
alanyl]-S-phenylglycine t-butyl ester (DAPT) to prevent Notch 
receptor cleavage. We co-cultured MDA-MB-231 cells with 
Jagged1 ligand-expressing mouse cells to activate endogenous 
Notch. This induced HEY genes in control cells, and the induc-
tion was blocked by DAPT (Fig. 3 C). In contrast, up-regulation 
of HEY genes by RBPJ knockdown in ligand-stimulated cells 
was not affected by DAPT treatment, indicating up-regulation 
of these target genes independent of Notch receptor activa-
tion (Fig. 3 D). Similarly, HEY expression was significantly 
increased in DG75 RBPJ/ tumors compared with RBPJ-
expressing controls and was not affected by DAPT-mediated 
Notch inhibition (unpublished data). These results imply that 
Figure 3. RBPJ depletion induces Notch target genes 
in a Notch-independent fashion. (A and B) Gene expres-
sion analysis of endpoint MDA-MB-231 tumors with data 
expressed as fold-change relative to the shRandom control, 
which corresponds to 1 on the y-axis. (A) Induction of HEY 
genes in shRBPJ tumors (n = 15, 90% RBPJ knockdown) com-
pared with shRandom tumors (n = 14). (B) Induction of HES1, 
SNAIL1, MMP1, and GUCY1A3 in shRBPJ tumors (n ≥ 8, >90% 
RBPJ knockdown) compared with shRandom tumors (n ≥ 8). 
(C and D) Endogenous Notch signaling was induced in MDA-
MB-231 cells by Jagged1 ligand stimulation, followed by 
gene expression analysis (n = 5). Data are expressed as  
fold change relative to shRandom + vehicle (DMSO).  
(C) HEY induction in shRandom cells is abolished by blocking 
Notch activation using 10 µM DAPT. (D) DAPT treatment on 
the magnitude of HEY gene induction in shRBPJ cells (≥80% 
RBPJ knockdown). (E) Mean Notch signature score in a total 
of 828 invasive TCGA breast cancers comparing the subset 
with RBPJ loss (n = 277) to those without (neutral, n = 551). 
The Notch gene signature identified in T-ALL cell lines  
(Margolin et al., 2009) was used to assign a score. (F) Data from 
E plotted by RBPJ copy number status; HD (n = 7), loss  
(n = 270), neutral (n = 489), and amplification (gain, n = 62). 
P < 0.0001 by Kruskal–Wallis followed by Dunn’s multiple 
comparisons post-test showed a significant difference only 
between the HD versus neutral, loss versus neutral and gain 
versus neutral group. For A, B, and E, p-values were obtained 
using a Mann-Whitney test and a Kruskal-Wallis one-way 
analysis of variance test for F and data are presented as 
mean + SEM. P-values for C and D were obtained using  
a Student’s t tests and data are presented as mean + SD.  
*, P < 0.05; **, P < 0.005; ***, P < 0.0005.
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occupancy at the HEY2 promoter, corroborating the EMSA 
data (Fig. 4 B). Transcriptional repression by the RBPJ core-
pressor complex depends on histone deacetylase activity, which 
condenses chromatin and silences gene expression (Borggrefe 
and Oswald, 2009). To confirm HEY promoter activation, we 
demonstrated that RBPJ depletion resulted in histone acety-
lation by acetylated histone H4 (H4ac) ChIP followed by 
the vacant RBPJ motif in RBPJ-depleted cells. Electropho-
retic mobility shift assays (EMSAs) in control and shRBPJ 
MDA-MB-231 cells did not reveal binding of alternate tran-
scription factors to the RBPJ consensus sequences of the 
HEY1 (not depicted) and HEY2 promoters of RBPJ-depleted 
cells (Fig. 4 A). We also performed local chromatin immuno-
precipitation (ChIP) in these cells confirming reduced RBPJ 
Figure 4. RBPJ depletion in MDA-MB-231 cells results in histone changes corresponding to promoter activity. (A) EMSA was performed using 
MDA-MB-231 nuclear lysates (n = 1) and labeled probes representing two RBPJ binding sites in the HEY2 promoter (HEY2: 160 to 167 and +41 to 
+48 bp from the TSS) in the absence or presence of excess unlabeled mutated probe (+mt) or excess wild-type probe (wt). Comparable results were ob-
tained using binding sites in the HEY1 promoter (not depicted). (B–E) ChIP analysis of the HEY2 promoter (n = 1) with fold enrichment calculated as  
2(Ct IgG  Ct target). Bound fragments were quantified by RT-qPCR with primers spanning the 160 bp RBPJ binding site in the promoter and the TSS. (B) RBPJ 
ChIP. (C) H4ac ChIP. (D) H3K4me3 ChIP. (E) H3K9me3 ChIP. (F and H) Locations of genome-wide 500 bp H4ac-differentially enriched regions identified by 
ChIP-seq (corrected P ≤ 0.005) relative to 38,405 nonredundant UCSC gene TSSs. Solid lines show random expectations (n = 20) for shRBPJ (blue) and 
shRandom (green). (F) Empirical distribution functions for the distance from the nearest TSS to the center of a differentially enriched (DE) region in the 
shRBPJ (blue) and the shRandom (green) control. Shaded blue regions that extend to 1 and 2 kb mark distances within which, for shRBPJ data, differen-
tially enriched regions are spatially concentrated relative to TSSs. (G) Overview (±100 kb) and detailed (±6 kb) histograms of directional distance between 
a differentially enriched region center and its nearest TSS. The shaded blue rectangle in the detailed view marks the 2/+1 kb TSS regions used in analy-
ses. (H) Fold change in the H4ac signal correlates with fold change in mRNA expression (RT-qPCR) evaluated for a subset of the 114 TSSs that were sig-
nificantly differentially enriched in the knockdown relative to shRandom cells, which correspond to 1 (Pearson correlation P = 0.006).
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Hence, RBPJ loss effects histone marks at promoters of ex-
pressed genes.
To define derepressed/activated promoter regions in RBPJ-
depleted cells genome-wide, we profiled H4ac enrichment 
by ChIP-sequencing (seq), and then used edgeR (Robinson 
et al., 2010) to assess differential H4ac enrichment in 500 bp 
genome-wide regions in shRBPJ (knockdown) versus shRan-
dom (control) MDA-MB-231 cells and retained regions that 
had a Benjamini-Hochberg corrected P < 0.005 (Benjamini 
and Hochberg, 1995). H4ac was differentially enriched in 
real-time quantitative PCR (RT-qPCR; Fig. 4 C). Histone 
H3 lysine4 tri-methylation (H3K4me3), an alternate mark 
of active gene promoters, was similarly enriched at the 
RBPJ binding site of the HEY2 promoter in RBPJ-depleted 
cells (Fig. 4 D). Histone H3 lysine9 tri-methylation (H3K9me3), 
a modification associated with transcriptional repression, was 
reduced across the HEY2 transcription start site (TSS) in 
RBPJ-depleted cells (Fig. 4 E). The modest increase in 
H3K9me3 at the RBPJ binding site may result from feed-
back mechanisms after RBPJ depletion and HEY2 induction. 
Figure 5. RBPJ deficiency increases mammosphere formation and confers resistance to cell death in breast cancer cells. (A and B) Mammo-
sphere formation evaluated in MCF10A, a breast epithelial cell line. (A) Representative images of mammospheres formed on day 7 per 10,000 initiating 
cells from shRandom control cells and shRBPJ cells (bars, 100 µm). (B) Quantification of mammospheres from three independent experiments after 7 d of 
culture. (C) MDA-MB-231 cell survival in vitro after suspension for 48 h (n = 4). (D) Staining and quantitative mapping of multiple markers in MDA-MB-
231 whole tumor cryosections. shRandom control tumors were harvested on the same day (time-matched), or when they reached comparable size  
(size-matched) to shRBPJ tumors. Representative images with TUNEL staining of dead cells (red), hypoxic areas with pimonidazole (green), S-phase  
proliferating cells with BrdU (black), vasculature with CD31 (blue) and gray tumor tissue boundaries with hematoxylin (bars, 500 µm). (E and F) Quantifi-
cation of TUNEL staining shown in D (n = 7 for each group) in the whole section (E) or with confluent cell death excluded (F). (G) TUNEL labeling of cell 
death and pimonidazole staining of hypoxic cells was evaluated as a function of the distance from nearest CD31 stained vasculature. Lines represent 
averaged data for each group. Solid lines are TUNEL staining and dashed line are pimonidazole data (n = 7 for each group). (H and I) Quantification of 
CD31- (H) and BrdU (I)-positive staining in MDA-MB-231 viable tumor tissue (n = 7 for each group). P-values for C were obtained from a Student’s t test 
and data are presented as mean + SD. P-values for E, F, H, and I were obtained using a Mann-Whitney test and bars are presented as mean + SEM.  
*, P ≤ 0.05; **, P < 0.005; ***, P ≤ 0.001.
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UCKL1, PMEPA1, DGAT1, CR612603, MCF2L2, and 
ZDHHC14) of the 114 genes that we identified as differen-
tially enriched in RBPJ knockdown cells at 2/+1 kb from 
the TSS have an RBPJ peak within 2 kb of the TSS. These re-
sults indicate that RBPJ depletion enriches for histone H4 
acetylation near TSSs.
RBPJ deficiency increases tumor cell survival
To clarify how genes whose promoters were associated with 
H4ac changes contribute to increased tumorigenicity, we used 
Ingenuity Pathway Analysis software to identify statistically 
significant biological functions for the genes corresponding 
to the 114 differentially enriched promoter regions in RBPJ 
knockdown cells. The 92 genes mapped by Ingenuity Pathway 
Analysis returned five significant cellular functions (Benjamini-
Hochberg corrected P ≤ 0.025): lipid metabolism, molecular 
transport, small molecule biochemistry, cell death, and cellu-
lar compromise.
Because all of the induced genes that were marked with 
H4ac, except TREML2, appeared in the cell death function, 
we evaluated whether the apoptotic response was altered 
in RBPJ-depleted cells. We first performed mammosphere 
formation assays, which enrich for breast cancer stem cells 
with aberrant self-renewal, using a nontumorigenic breast epi-
thelial cell line MCF10A transduced with shRandom and 
shRBPJ constructs. RBPJ knockdown increased mammo-
sphere formation up to 3.7-fold (Fig. 5, A and B). Next, we 
incubated MDA-MB-231 cells in suspension for 48 h to 
induce anoikis. Compared with control cells, RBPJ knock-
down markedly protected cells from death resulting from loss 
of cell matrix attachment (Fig. 5 C). To confirm that RBPJ 
shRBPJ cells relative to shRandom in regions that extended 
from approximately 2 kb to +1 kb relative to TSSs, whereas 
for regions that were differentially enriched in the shRandom 
versus shRBPJ cells the spatial distribution was comparable to 
random expectation (Fig. 4, F and G). Consistent with this, in 
human T lymphoblastic leukemia cells the majority of RBPJ 
and Notch1 binding sites were found within 2 kb of TSSs 
(Wang et al., 2011). Assessing differential H4ac enrichment in 
2/+1 kb regions for all 38,405 nonredundant UCSC gene 
TSSs, and retaining only regions that had an H4ac fold change 
of at least 2 and a Benjamini-Hochberg corrected P < 0.005, 
we identified 114 TSS regions that were differentially en-
riched in RBPJ knockdown cells (Table S3). For nine of the 
differentially expressed genes, we used RT-qPCR to confirm 
that H4ac enrichment was associated with increased mRNA 
expression (Fig. 4 H). Within regions 2/+1 kb from the 
TSS, eight of the nine genes had an RBPJ binding affinity 
score that was above the median for the global set of 38,405 
regions, and for all nine TSS regions we identified a putative 
RBPJ binding site as a high-scoring match (>0.96) to a TGG-
GAA de novo sequence motif (Aerts et al., 2005; Roider 
et al., 2007; unpublished data). To further evaluate whether 
promoters differentially marked with H4ac are associated with 
genes previously identified as bound by RBPJ, we obtained 
2,112 RBPJ binding sites in the CUTLL1 T-lymphoblastic 
leukemia/lymphoma cell line (Wang et al., 2011). Evaluating 
these RBPJ ChIP-seq peaks against our genome-wide H4ac 
differentially enriched regions at an absolute distance of 2 kb 
from the TSS showed concordance in RBPJ knockdown 
regions (P = 2.5 × 104) compared with control H4ac re-
gions or random expectations (P = 0.11). Eight (HEY1, HES1, 
Figure 6. Complete RBPJ loss confers resis-
tance to cell death in DG75 lymphoma cells. 
(A) DG75 cell survival after induction of cell death 
with 100 µM tert-Butyl hydroperoxide (TBHP,  
n = 3). (B) Staining and quantitative mapping of 
multiple markers in DG75 whole tumor cryosec-
tions. Parental tumors were harvested when they 
reached a comparable size to RBPJ/ tumors. 
Representative images with TUNEL staining of 
dead cells (red), hypoxic areas with pimonidazole 
(green), S-phase proliferating cells with BrdU 
(black), vasculature with CD31 (blue), and gray 
tumor tissue boundaries with hematoxylin (bars, 
300 µm). (C and D) Quantification of TUNEL stain-
ing shown in B (n = 7 for each group) in the 
whole section (C) or with confluent cell death 
excluded (D). (E) TUNEL and pimonidazole staining 
was evaluated as a function of the distance from 
nearest vasculature. For TUNEL data, n = 7 for 
each group. For pimonidazole data, n = 5 for 
DG75 RBPJ/ and n = 4 for DG75 parental.  
P-values for A were obtained from a Student’s t test 
and data are presented as mean + SD. P-values 
for C and D were obtained using a Mann-Whitney 
test and bars are presented as mean + SEM.  
*, P < 0.05; **, P < 0.005.
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MYC and NF-B contribute to increased survival  
in RBPJ-deficient cancer cells
To identify transcription factors that may contribute to gene 
activation in the context of RBPJ depletion, we compared the 
spatial concordance between the genome-wide 500 bp H4ac 
differentially enriched regions in MDA-MB-231 cells and the 
in vivo binding regions reported for 52 transcription factors 
in 24 cell lines (Fig. 7 A; Birney et al., 2007). Binding regions 
for MYC and NF-B were concentrated within 1,000 bp 
of the H4ac regions that were differentially enriched in the 
RBPJ knockdown cells (Materials and methods; Fig. 7 A). 
Evaluating 2,112 RBPJ binding sites from CUTLL T lym-
phoblastic leukemia/lymphoma cells (Wang et al., 2011), we 
also found enrichment of NF-B and MYC binding regions 
(within 500 bp of the binding site; Fig. 7, B and C). For the 
114 genes that were differentially enriched in RBPJ knock-
down cells, binding motifs for these two factors were among 
the most highly enriched within regions up to 1 kb upstream 
of the TSS (Zambelli et al., 2009; unpublished data). Both 
transcription factors have previously been shown to coopera-
tively regulate transcription of a common set of target genes 
with Notch (Lee et al., 2000; Margolin et al., 2009; Barbarulo 
et al., 2011).
To determine whether MYC and NF-B–mediated acti-
vation are required to promote survival in RBPJ-depleted 
cells, we performed anoikis assays in the presence of inhibi-
tors against MYC (10058-F4) or NF-B (BSM-345541, an 
I-Kappa-B kinase  inhibitor; Burke et al., 2003). Inhibition 
of either pathway abolished the survival advantage observed 
with RBPJ loss, resulting in cell death comparable to shRandom 
deficiency also conferred a survival advantage in vivo, we 
used terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) to mark all dead cells in tumor cryosec-
tions. Both MDA-MB-231 size-matched shRandom control 
tumors, which were collected when they reached a compa-
rable size to the RBPJ-knockdown tumors, and shRandom 
time-matched control tumors, which were harvested at the 
same time as the RBPJ-knockdown tumors, showed in-
creased TUNEL staining compared with RBPJ-depleted 
tumors (Fig. 5, D–F).
We also stained for and quantified vasculature, hypoxic 
areas, and proliferating cells in tumor sections (Fig. 5, D and 
G–I). The difference in cell death between control and 
RBPJ-depleted tumors was especially pronounced in regions 
at further distances from blood vessels where hypoxia is 
highest (Fig. 5 G). Microvessel density (quantified by CD31 
staining) and proliferation (quantified by BrdU staining) was 
also significantly increased in shRBPJ tumors compared 
with both time-matched and size-matched control tumors 
(Fig. 5, H and I).
We confirmed our findings in the DG75 lymphoma line, 
where RBPJ deficiency significantly reduced apoptosis in vitro 
and in vivo compared with parental cell xenografts (Fig. 6, 
A–E). This cell death was more pronounced at increasing dis-
tances from the vasculature, consistent with the findings in 
MDA-MB-231 xenografts (Fig. 6 E). However, no difference 
was observed in CD31 or BrdU staining in DG75 tumors 
(unpublished data). These data suggest that a common pheno-
type with RBPJ loss is an increase in survival of tumor cells 
in vivo.
Figure 7. MYC and NF-B binding re-
gions are associated with H4ac changes 
and are near RBPJ binding regions.  
(A) Spatial association between genome-wide 
500 bp H4ac regions in MDA-MB-231 cells 
and ENCODE ChIP-seq data for 52 transcrip-
tion factors and input DNA in 24 cell lines 
(Birney et al., 2007). The bar chart shows the 
fractions of H4ac differentially enriched (DE) 
regions with centers within 1 kb of the center 
of an enriched transcription factor region.  
(B and C) Concordance between RBPJ ChIP-
Seq peaks and NF-B and MYC binding re-
gions. Spatial relationship between 2112 
ChIP-seq enriched RBPJ peaks in CUTLL cells 
(Wang et al., 2011) and ChIP-seq enriched 
regions reported for NF-B p65 (B) and MYC 
(C) in ENCODE data (Birney et al., 2007). Em-
pirical distribution functions for distances 
between the center of a thresholded ENCODE 
peak and the center of the nearest RBPJ peak 
region, contrasted to the distribution function 
when RBPJ peak locations on each chromo-
some were randomized.
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growth in two cancer cell lines derived from distinct tumor 
types in which RBPJ is targeted using two methods, shRNA-
mediated knockdown or genetic ablation. Although we pres-
ent data on breast cancer and lymphoma as model systems, we 
provide additional clinical data supporting RBPJ loss in other 
human malignancies, such as lung cancers, through either or 
both RBPJ copy number loss or reduced mRNA expression. 
Supporting our observations, depletion of RBPJ was also re-
ported to enhance eye tumor growth and metastases in Dro-
sophila (Liefke et al., 2010).
RBPJ depletion causes a similar outcome to Notch activa-
tion in promoting tumor growth. Our current and previous 
work supports that retaining RBPJ transcriptional repression 
through blockade of Notch (by preventing Notch cleavage 
or transcriptional activation) inhibits MDA-MB-231 tumor 
growth (Leong et al., 2007). Conversely, RBPJ deficiency 
causes up-regulation of recognized Notch target genes, such 
as those of the HEY gene family, even in the presence of DAPT 
which inhibits Notch receptor processing and activation. We 
used a gamma secretase inhibitor to block signaling from all 
Notch receptors by preventing receptor activation at the 
membrane. Our aim was to perturb the Notch axis at a site up-
stream of the NotchIC–MAML–RBPJ ternary complex and 
show that the signal triggered by RBPJ loss is independent of 
MDA-MB-231 cells (Fig. 8, A and B). BSM-345541 also sig-
nificantly reduced HEY gene expression up-regulated by RBPJ 
knockdown (Fig. 8 C). To further define which NF-B fam-
ily members are required for survival activity in MDA-MB-231 
cells, we used siRNA to deplete NF-B1 (processed to p50), 
NF-B2 (processed to p52), RELA/p65, RELB, and REL 
(c-Rel). Knockdown of either NFKB1 or the combined knock-
down of RELB and REL abolished the survival advantage 
conferred by RBPJ depletion, suggesting that a combination 
of RELB/p50 and REL/p50 heterodimers may be responsi-
ble for the survival activity in shRBPJ MDA-MB-231 cells 
(Fig. 8 D). Finally, we observed a trend for enriched NF-B 
(p50) and MYC binding at the HEY2 promoter in RBPJ- 
depleted MDA-MB-231 cells (Fig. 8, E and F). Hence, loss of 
RBPJ-mediated repression may enable nuclear signaling by 
NF-B and MYC activating prosurvival signaling pathways.
DISCUSSION
Our results indicate that depletion of RBPJ leads to gene in-
duction of RBPJ-bound promoters, increased cell survival, 
and enhanced tumorigenicity. In contrast to NOTCH1, RBPJ 
expression is frequently reduced in several primary human 
tumor types including up to 33% of invasive breast cancer 
cases. We further show that RBPJ deficiency promotes tumor 
Figure 8. MYC and NF-B contribute to survival in RBPJ-deficient MDA-MB-231 cells. (A and B) Cell death after forced suspension and treatment 
with indicated agents for 48 h. (A) Vehicle control (DMSO) or 80 µM 10058-F4 (n = 3). (B) Vehicle control (DMSO) or 25 µM BSM-345541 (BSM, n = 4).  
(C) Gene expression analysis in MDA-MB-231 cells transduced with shRBPJ or shRandom after treatment with vehicle (DMSO) or 25 µM BSM (n = 3). Data are 
expressed as fold-change relative to shRandom + vehicle. (D) Transfection with control small inhibitory (si)-RNA (siControl), siNFKB1, siNFKB2, siRELA, siRELB, 
and/or siREL (n ≥ 3). P-values are reported for treatments that significantly increased cell death in shRBPJ-expressing cells relative to the siControl. (E and F) 
ChIP analysis of the HEY2 promoter with fold enrichment calculated as 2(Ct IgG  Ct target). Bound fragments were quantified by RT-qPCR with primers spanning 
the 160 bp RBPJ binding site in the HEY2 promoter and the HEY2 TSS (E) NF-B (p50) ChIP (n = 5). (F) MYC ChIP (n = 3). P-values for A–D were obtained 
from a Student’s t test and data are presented as mean + SD. For E and F, data are presented as SEM. *, P < 0.05; **, P < 0.005; ***, P < 0.0005.
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for a Notch-independent role for RBPJ. These Notch-inde-
pendent genes may also be susceptible to derepression upon 
RBPJ depletion.
Several lines of evidence support that Notch is associated 
with conferring protection against cell death and is an impor-
tant mediator of tumor cell survival (Capaccione and Pine, 2013). 
We have previously shown that expression of constitutively 
active Notch increases the resistance of MCF10A, a breast 
epithelial cell line, to anoikis and others have demonstrated 
induction of hyperproliferative acinar structures and colonies 
in soft agar (Leong et al., 2007; Mazzone et al., 2010). Com-
patible with a role in inhibiting apoptosis, mammary-specific 
deletion of Rbpj did not block Notch-induced tumor forma-
tion (Raafat et al., 2009). Rather, Notch-induced mammary 
tumors on a mammary-specific Rbpj/ background showed 
reduced apoptosis compared with tumors containing func-
tional Rbpj. Although the interpretation in this study was that 
Notch has Rbpj-independent oncogenic activity, our findings 
suggest that RBPJ loss prevents tumor cell death independent 
of Notch receptor activation, thereby promoting tumorigen-
esis. We observed reduced cell death as a common phenotype 
resulting from RBPJ deficiency in two distinct cancer models 
in vivo, which was especially pronounced in hypoxic areas of 
tumor tissue. These harsher tumor microenvironments have 
limited oxygen and nutrient supply and have been proposed 
to be the origin of more aggressive cells (Vaupel, 2004). RBPJ 
depletion may also contribute to increased proliferation and 
angiogenesis, as shRBPJ MDA-MB-231 tumors showed sig-
nificantly increased BrdU and CD31 staining.
Loss of RBPJ-mediated repression may enable nuclear 
signaling by MYC and NF-B, which allows increased survival. 
Both these signaling pathways are thought to be activated in 
MDA-MB-231 cells and MYC and NF-B have previously 
been shown to cooperatively regulate transcription of a com-
mon set of target genes with Notch (Nakshatri et al., 1997; 
Lee et al., 2000; Cappellen et al., 2007; Margolin et al., 2009; 
Barbarulo et al., 2011). In RBPJ-deficient cells, NF-B and 
MYC binding was enriched at the HEY2 promoter and each 
of these pathways was required for protection against anoikis. 
Further, treatment with an inhibitor of NF-B signaling re-
duced HEY gene expression up-regulated by RBPJ knockdown. 
Recently MYC has been shown to be a general amplifier of 
actively transcribed genes in tumor cells rather than binding 
and regulating a new set of genes (Lin et al., 2012). Hence 
MYC may amplify the output of the existing derepressed genes 
resulting from RBPJ knockdown. Our data suggest that in the 
absence of RBPJ, enhanced tumor cell survival is associated 
with MYC- and NF-B–driven prosurvival mechanisms.
Here, we describe a novel mechanism of cancer progression 
in mammalian cells that involves loss of RBPJ, the primary 
transcriptional mediator of canonical Notch signaling. The 
signal associated with loss of RBPJ overlaps with but is not 
identical to Notch activation. Indeed, Notch receptor activa-
tion is not required to drive the signal generated with RBPJ 
loss, but rather the signals are mediated in part by NF-B and 
MYC. Although Notch activation and RBPJ depletion may 
Notch receptor activation. Derepression upon RBPJ removal 
also extends to other Notch receptor target genes. In our 
analysis of 828 invasive human breast cancers, cases with RBPJ 
loss were associated with an increased Notch signature score 
compared with tumors without RBPJ loss. Of these cases, 
breast cancers with RBPJ HD and copy loss had a signifi-
cantly higher Notch signature score compared with samples 
with neutral RBPJ copy number. However, cases with RBPJ 
copy gain also showed an increased Notch signature score 
compared with samples with neutral RBPJ copy number, al-
though RBPJ HD samples tended to have a higher Notch 
score than either of those with RBPJ copy loss or gain. In 
samples with gene amplification, increased RBPJ presumably 
facilitates transcriptional activation in response to Notch re-
ceptor activity. Together, our data support that target gene 
expression is not solely an indicator of Notch receptor activ-
ity, as RBPJ depletion represents an alternate mechanism for 
promoting tumor growth and HEY expression.
RBPJ is ubiquitously expressed in normal tissue having 
a promoter sequence characteristic of a housekeeping gene 
(Hamaguchi et al., 1992; Kawaichi et al., 1992). In the absence 
of Notch activation, RBPJ is a default transcriptional repres-
sor and enters the nucleus precommitted to this function, 
which depends on histone deacetylase activity to condenses 
chromatin and silences gene expression (Zhou and Hayward, 
2001; Borggrefe and Oswald, 2009). Conversely, our findings 
show that depletion of the RBPJ protein at RBPJ binding 
sites caused enrichment of both H3K4me3 and H4ac, histone 
marks associated with active promoters. H3K9me3, a modifi-
cation associated with transcriptional repression, was more 
modestly increased at the HEY2 RBPJ binding site but was 
reduced across the HEY2 TSS in RBPJ knockdown cells. Our 
data support that RBPJ loss results in epigenetic changes that 
allow promoter activity. As preexisting RBPJ occupancy is re-
quired for gene repression in the absence of Notch activation 
at these promoters, these genes would be expected to be par-
ticularly susceptible to derepression upon RBPJ removal.
In Drosophila, active Notch can recruit RBPJ to promot-
ers where it was previously not bound (Krejcí and Bray, 2007). 
RBPJ is likely not required for the repression of these genes 
but only for transcriptional activation via Notch. Thus loss of 
RBPJ may both derepress a subset of Notch target genes and 
potentially block Notch signaling at other targets. Further, 
Notch-independent RBPJ signaling has been reported. Dur-
ing early pancreatic and neural development, the Ptf1a–RBPJ 
complex regulates gene transcription independently of Notch 
(Beres et al., 2006; Hori et al., 2008). In a human T lympho-
blastic leukemia/lymphoma cell line, RBPJ sites were identi-
fied that do not bind Notch1. Only 36% of Notch1 binding 
sites were found to overlap with RBPJ binding sites and 66% 
of RBPJ sites overlapped with Notch1 sites as evaluated by 
ChIP-seq (Wang et al., 2011). Viral proteins can also co-opt 
RBPJ to allow for their own propagation via induction of viral 
and cellular promoters (Hayward, 2004; Persson and Wilson, 
2010). Interestingly, fungal species lack Notch but have RBPJ 
genes (Prevorovský et al., 2009) providing additional support 
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Annexin V/propidium iodide negative) or dying cells (Annexin V and/or 
propidium iodide positive) relative to untreated attached (MDA-MB-231) or 
untreated (DG75) cells within each group.
RNA interference and gene transfer. shRNA-encoding DNA oligo-
nucleotides (Integrated DNA Technologies) were cloned into the HpaI and 
XhoI site of the pLentilox3.7 green fluorescent protein (GFP) lentiviral vec-
tor (gift from L. Van Parijs, Massachusetts Institute of Technology, Cambridge, 
MA; Rubinson et al., 2003). The targeting sequences are as follows: shRandom, 
human shRBPJ, and shRBPJ-set2 have been previously described (Niessen 
et al., 2008; NM_015874); shScrambled, 5-GATTAGAACCCTCACGG-
TACG-3. For overexpression, the following retroviral vectors, all of which 
encoded human genes, were used: pLNCX (gift from A.D. Miller, Fred 
Hutchinson Cancer Research Centre, Seattle, WA), pLNC-FlagRBP2N, 
pLNC-FlagRBP2NR179H (the mutated RBPJ; MacKenzie et al., 2004), 
MIY, and pMIY-Jagged1. Target cells were transduced and purified based on 
GFP or YFP expression by flow sorting using a FACS-440 flow-sorter (BD). 
Cell lines expressing LNCX constructs were selected with 300 µg/ml G418 
(Invitrogen). Knockdown and overexpression were assessed by RT-qPCR 
and immunoblotting.
RNA isolation and RT-qPCR. Total RNA was extracted using TRIzol 
(Invitrogen) according to the manufacturers’ recommendations. First-strand 
cDNA was synthesized using Superscript II Reverse transcription (Invitro-
gen) and RT-qPCR was performed using the ABI Prism 7900HT detection 
system (Applied Biosystems) and the SYBR Green PCR Master Mix kit 
(Applied Biosystems), with gene-specific primer pairs (Table S4). Data ob-
tained from the RT-qPCR reaction was analyzed using the comparative 
threshold cycle (Ct) method (User Bulletin No. 2; PerkinElmer Life Sci-
ences) with GAPDH used as the reference gene for normalization.
Immunoblotting. Cultured cells and tumor tissues were lysed, resolved by 
SDS-PAGE, and probed overnight with primary antibodies using the fol-
lowing dilutions: 1:1,000 rat anti-RBPJ clone number 76719 (Institute of 
Immunology), and 1:10,000 mouse anti -tubulin (Sigma-Aldrich).
EMSA. Nuclear lysates were collected from shRandom, shRBPJ, and shRBPJ-
set2 overexpressing MDA-MB-231 cells for the RBPJ EMSA assays. In brief, 
the cells were washed two times with PBS, resuspended in four pellet vol-
umes of buffer A (10 mM Hepes-KOH, pH 7.8, 10 mM KCl, 1.5 mM 
MgCl2, 5 mM with addition of a protease inhibitor cocktail; all from Sigma-
Aldrich), pelleted for 15 s at 12,000 g and resuspended in 375 µl buffer 
A containing 0.5% NP-40 (Sigma-Aldrich). After mixing, cells were incubated 
at 4°C for 10 min to lyse the cells, centrifuged for 10 min at 12,000 g at 4°C, 
and the cytosolic extract was removed. The nuclei were washed once with 
buffer A and resuspended in three pellet volumes of buffer B (50 mM Hepes-
KOH, pH 7.8, 10% glycerol, 50 mM KCl, 300 mM NaCl2, and 0.1 mM 
EDTA, with addition of a protease inhibitor cocktail; all from Sigma- 
Aldrich) and incubated at 4°C for 20 min. The nuclear lysates were collected 
after centrifugation for 10 min at 12,000 g at 4°C and stored at 80°C. The 
oligonucleotides containing RBPJ wild-type or mt motifs in the HEY2 pro-
moter (Table S4) were end-labeled with 32P dCTP using the Klenow frag-
ment of DNA Polymerase I. The binding reaction (10 mM TrisHCl, 50 mM 
NaCl, 1 mM EDTA, pH 8, 4% glycerol, and 2 µg PolydI-dC binding buffer; 
all from Sigma-Aldrich), and 10 µg of nuclear protein was performed by pre-
incubating with either 50-fold excess wild-type or mt (Noseda et al., 2006) 
nonradioactive duplex oligos for 15 min on ice, and then adding a 150,000-cpm 
32P-labeled double-stranded probe and incubating for 30 min at room tem-
perature. DNA–protein complexes were electrophoresed on 5% Tris-Borate 
EDTA gels, dried, and exposed to a phosphorimager plate for 16 h.
Tumor xenografts. All protocols involving mice were evaluated and ap-
proved by the University of British Columbia Animal Care and Ethics Com-
mittee. Female non-obese diabetic/severe combined immunodeficient mice 
(NOD/SCID, Animal Resource Centre of the British Columbia Cancer 
not be equivalent, loss of RBPJ represents an alternate means 
of deregulating a component of the Notch signaling cascade, 
and so has therapeutic implications, as specific inhibition of 
Notch processing or function would be predicted to not have 
beneficial effects on tumors with RBPJ loss. Further, in cancers 
lacking RBPJ, targeting other oncogenic signals that con-
tribute to survival, such as MYC or NF-B, may be a thera-
peutic option.
MATERIALS AND METHODS
Cell culture. The human DG75 Burkitt’s lymphoma parental and RBPJ/ 
cell lines (Maier et al., 2005) were grown in RPMI 1640 medium (Sigma-
Aldrich) supplemented with 10% heat-inactivated fetal bovine serum 
(HyClone), 2 mM glutamine (Invitrogen), and 100 U of each penicillin and 
streptomycin. MDA-MB-231 human breast carcinoma cells, viral producer 
line 293T, and AmphoPhoenix were cultured in DMEM (Sigma-Aldrich) 
and supplemented as above. For co-culture experiments, 105 MDA-MB-231 
shRandom or shRBPJ cells were co-cultured with 105 mouse SVEC4-10 
endothelial cells transduced with MSCV-IRES-yellow fluorescent protein 
(MIY) control vector or MIY-Jagged1. Cells were plated in 12-well tissue 
culture dishes in media containing either 10 µM DAPT (EMD Millipore) or 
DMSO vehicle control (Invitrogen). Cells were harvested after 48 h of co-
culture and RT-qPCR was performed with human-specific primers to avoid 
amplification of mouse transcripts. The normal breast epithelial cell line 
MCF10A was culture in a 1:1 mixture of DMEM/F12 supplemented with 
5% horse serum, 2 mM glutamine, 20 ng/ml epidermal growth factor (all 
from Sigma-Aldrich), 100 ng/ml cholera toxin (Cederlane), 10 µg/ml insulin 
(Sigma-Aldrich), 500 ng/ml hydrocortisone (Sigma-Aldrich), and 100 U/ml 
each of penicillin and streptomycin (Invitrogen). All cells were maintained 
at 37°C in a 5% CO2 atmosphere.
Mammosphere culture. MCF10A human breast epithelial cells were sus-
pended in MammoCult complete medium containing growth supplements 
heparin sulfate and hydrocortisone according to the manufacturer’s instructions 
(Stem Cell Technologies). Mammospheres were cultured according to the 
MammoCult product sheet. In brief, the cell suspension was passed through 
a 45-µm cell strainer to obtain single cells. 10,000 MCF10A cells were seeded 
into each well of a 6-well ultra-low adherence dish (Stem Cell Technologies) 
containing 2 ml MammoCult complete medium. After 7 d in culture at 
5% CO2 at 37°C, spheres >60 µm in diameter were counted.
Cell death assay. Anoikis experiments were performed with MDA-MB-
231 cells by plating 2.5 × 105 cells/well in Costar low-attachment 6-well 
plates (Stem Cell Technologies). Cells were then incubated in suspension for 
48 h. BSM-345541 (EMD Biosciences) or 10058-F4 (Sigma-Aldrich) was 
added upon cell plating. In experiments where siRNA was used, cells were 
first transfected using Lipofectamine RNAiMax (Invitrogen) and then col-
lected 24 h later for plating for the anoikis assay. AllStars negative control, 
NF-B1 (Hs_NFkB1_7), NF-B2 (Hs_NFkB2_9), RELA (Hs_RELA_7), 
RELB (Hs_RELB_5), and cREL (Hs_REL_5) siRNA were obtained from 
QIAGEN. For treatment with 100 µM tert-butyl hydroperoxide (TBHP; 
Molecular Probes; Invitrogen), DG75 cells were plated at 7.5 × 105 cells/well 
in a 6-well plate and treated for 2 h to induce death. To quantify the surviving 
fraction, cells were harvested (for MDA-MB-231 cells the supernatant, PBS 
wash, and adherent cells were pooled). Cells were then pelleted, washed once 
with cold PBS, and resuspended in 100 µl Annexin V binding buffer (10 mM 
Hepes, 140 mM NaCl, and 2.5 mM CaCl2, pH 7.4; all from Sigma-Aldrich). 
After addition of 5 µl Annexin V–488 to DG75 cells or Annexin V–APC to 
MDA-MB-231 cells (both fluorescent conjugates from Invitrogen) and 5 µl 
propidium iodide (1 mg/ml; Sigma-Aldrich) per tube, the reaction was incu-
bated for 15 min. 500 µl of ice-cold Annexin V binding buffer was added to 
each tube and flow cytometry analysis was performed immediately using the 
EPIC Elite flow cytometer (Beckman Coulter) and FCS Express (De Novo 
Software). Data are expressed as the proportion of surviving cells (defined as 
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and then stained with hematoxylin and eosin. For immunohistochemical 
analysis, antigen retrieval was performed with a Pascal decloaker (Dako) 
using citrate buffer, pH 6.0 (Dako). The rat anti-RBPJ7A11 antibody (Maier 
et al., 2005) and IgG2Bkappa control (BD) were used as primary antibodies 
at a 1:10 dilution. The slides were stained using the avidin-biotin-peroxidase 
method with the EnVision Flex kit (Dako) as per manufacturer’s instructions, 
a 1:50 dilution of Biotin-SP-AffiniPure donkey anti–rat secondary (Medi-
corp Inc.), and 1:500 peroxidase-conjugated streptavidin (Medicorp Inc.) 
followed by the chromagen 3,3-diaminobenzidine (Dako) to develop the 
immunostain. All sections were counterstained with hematoxylin. 1.5% so-
dium bicarbonate was used as a bluing agent. Sections were imaged using 
a light microscope (BX41; Olympus). Tissue microarray slides were scanned 
with the imaging system (Aperio Technologies) and images were imported 
into ImageScope software (Aperio Technologies) for viewing and acquisition 
of micrographs. Immunophenotypic evaluation was performed indepen-
dently by two evaluators who scored the tissue microarrays for presence or 
absence of RBPJ.
Microarray data. Published microarray data were obtained from the fol-
lowing sources: Gene Expression Omnibus (GEO) accession nos. GSE5364 
(human breast cancer and adjacent nonmalignant tissue; Yu et al., 2008), 
GSE4824 (lung cancer cell lines; Lockwood et al., 2008), GSE3141 (111 
NSCLC tumors; Bild et al., 2006); and the Oncomine database (normalized 
breast cancer microarray data; Ginestier et al., 2006). In addition, data for 67 
normal human bronchial epithelial cells analyzed with the U133 plus array 
platform (Affymetrix), and 49 lung cancer samples analyzed with a custom 
chip (Affymetrix; Lockwood et al., 2010), were obtained from the System for 
Integrative Genomic Microarray Analysis (SIGMA) website (Chari et al., 
2006). Microarray data were log2 transformed.
TCGA data. RNA-seq RPKM (z-score) and copy number (GISTIC alter-
ation status) data for all genes of interest were downloaded for 828 inva-
sive breast cancers, 178 lung SqCC, and 129 lung AC from the MSKCC 
cBIO Cancer Genomics Portal (Cerami et al., 2012; Gao et al., 2013). For 
each tumor type, the expression of RBPJ was compared between samples 
with RBPJ copy number loss versus those without using the Mann-Whitney 
U-Test (two-tailed).
Array comparative genomic hybridization (aCGH). DNA copy num-
ber profiles were generated for 49 lung cancer samples using whole genome 
tiling path array comparative genomic hybridization. Details of the genomic 
array, DNA extraction, labeling and hybridization, image analysis, and nor-
malization have been described previously (Ishkanian et al., 2004). Data are 
available through the SIGMA website.
Notch signature score. We analyzed published microarray data (GEO ac-
cession no. GSE12868; Margolin et al., 2009) comparing 10 human T-ALL 
cell lines with Notch activating mutations treated with either DMSO or 
compound E. A total of 182 probes were identified as significantly down-
regulated by compound E treatment (Benjamini-Hochberg corrected P ≤ 
0.05 paired t test, one-tailed; Table S2). Probes were mapped to 170 annotated 
genes, 162 of which had an RNA-seq RPKM z-score in TCGA. Expres-
sion data for each gene was compiled for 828 invasive breast cancers using 
a method modified from Loboda et al. (2010) to determine the Notch signa-
ture score. In brief, the mean expression for compound E down-regulated 
genes (i.e., Notch-induced genes) was determined for each sample. The mean 
expression of compound E up-regulated genes was then subtracted to give 
a composite Notch pathway score for each sample. The scores were then 
compared between breast cancer samples with RBPJ loss versus those with-
out using the Mann-Whitney U-Test.
Histone, NF-B, and MYC ChIP. shRandom or shRBPJ ChIP samples 
were prepared from stable MDA-MB-231 cell lines grown to 70% confluence. 
In brief, cells were cross-linked with 1% formaldehyde for 10 min at room 
temperature, the reaction was quenched by addition of 0.125 M glycine, and 
Research Centre) were injected subcutaneously into the dorsa with human 
tumor cell lines. Tumor growth was monitored at the indicated times by exter-
nal measurements with calipers, and tumor volume calculated using the for-
mula (/6 × length × width × height). For MDA-MB-231 tumor studies, 
5 × 106 stably transduced cells were injected in 100 µl unsupplemented DMEM. 
For DG75 tumor studies, 107 cells were injected in 200 µl PBS. Individual tu-
mors were split for either fixation in 4% paraformaldehyde or freezing, and 
then used for histology, immunostaining, or RNA and protein analysis.
Whole section tumor staining. Tumor staining study protocols were simi-
lar to those previously reported (Kyle et al., 2003; Huxham et al., 2004). Mice 
were administered 1,500 mg/kg BrdU (Sigma-Aldrich) in 0.9% NaCl and 
60 mg/kg pimonidazole (Hypoxyprobe) by intraperitoneal injection 2 h before 
tumor excision. Harvested tumors were frozen at 20°C on an aluminum 
block, covered in embedding medium (O.C.T.) and stored at 80°C until 
sectioning. Cryosections 10 µm thick were obtained using a Cryosar HM560 
(Microm International GmbH; Thermo Fisher Scientific), dried overnight, and 
fixed in 50:50 acetone-methanol for 10 min at room temperature. Incorpo-
rated BrdU was detected using a monoclonal mouse anti-BrdU antibody (clone 
BU33; Sigma-Aldrich), followed by an anti–mouse peroxidase-conjugated 
antibody (Sigma-Aldrich) and a metal-enhanced 3,3-diaminobenzidine 
substrate (Pierce; Thermo Fisher Scientific). Hypoxic cells labeled with pi-
monidazole were detected using a polyclonal rabbit anti-pimonidazole anti-
body (Hypoxiprobe) and visualized with a fluorescent Alexa Fluor 488 tagged 
anti–rabbit secondary antibody. Vasculature was stained using a rat anti–mouse 
monoclonal antibody to CD31 (clone MEC 13.3; BD) and fluorescent Alexa 
Fluor 546 anti–rat secondary antibody (Invitrogen). TUNEL staining was 
performed using the in situ cell death detection kit (Roche) with a TMR 
red-tagged dUTP. After imaging of fluorescence, slides were placed in dis-
tilled water for 10 min and treated with 2 mol/liter HCl at room tempera-
ture for 1 h, followed by neutralization for 5 min in 0.1 mol/liter sodium 
borate and rinsing in PBS. Slides were counterstained with hematoxylin, de-
hydrated, and mounted using Permount (Thermo Fisher Scientific) before 
being imaged. Images were acquired using a fluorescence microscope (Im-
ager Z1; Carl Zeiss), a cooled, monochrome CCD camera (Retiga 4000R; 
QImaging), and motorized x-y stage (Ludl Electronic Products). This system 
allows tiling of adjacent fields of view to compile images of entire tumor 
cryosections at a resolution of 0.75 µm/pixel; sections were repeat-imaged at 
various points during staining. Using Image (National Institutes of Health) 
and user-supplied algorithms, images of BrdU, CD31, pimonidazole, TUNEL, 
and hematoxylin staining, all from the same tumor section, were overlaid and 
staining artifacts removed. Grayscale images of CD31 and TUNEL were in-
verted, thresholded, colorized (blue and red, respectively), and overlaid onto 
images of BrdU and hematoxylin (black and gray, respectively). Grayscale 
images of pimonidazole (green channel) were overlaid using Photoshop CS 
(version 8.0; Adobe) and combined using the multiply mask. Tumor tissues 
were analyzed either as whole tumor sections or as viable tissue only after 
crop and removal of confluent necrosis. TUNEL-positive staining was identi-
fied by selecting pixels a minimum of five standard deviations above tissue 
background levels and is reported as the fraction of TUNEL positive staining 
for whole sections or as the fraction of TUNEL-positive staining in viable 
tissue. BrdU-positive staining is reported as the fraction of positive pixels in 
viable tissue. Distribution analyses were performed in viable tissue only; each 
pixel in an image cropped to remove necrosis was sorted based on its distance 
relative to CD31-positive vasculature. For pimonidazole staining the mean 
pixel intensity is reported as a function of distance from vasculature, and for 
TUNEL analyses the fraction of pixels meeting or exceeding the stain thresh-
old is reported as a function of distance from nearest vasculature.
Immunohistochemistry. The breast cancer tissue microarray sections were 
cut from formalin-fixed, paraffin-embedded small-core biopsies placed in the 
same block. Xenograft tumors excised from mice were fixed overnight in 
10% phosphate-buffered formalin, progressively dehydrated through gradi-
ents of alcohol, and embedded in paraffin. Further analysis was performed by 
PMI Labs. In brief, 4-µm sections were cut, deparaffinized in xylene, rehydrated, 
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quality was assessed and quantified using an Agilent DNA 1000 series II assay 
(Agilent Technologies) and a 7500 spectrophotometer (Nanodrop), and sub-
sequently diluted to 10 nM. The final concentration was confirmed using 
a Quant-iT dsDNA HS assay kit and Qubit fluorometer (Invitrogen). Clusters 
were generated on Illumina cluster stations and were sequenced to 51 bp for 
shRBPJ and 76 bp for shRandom using GAIIx (Illumina), according to the 
manufacturer’s instructions. The sequence read data were submitted to the 
Sequence Read Archive with accession no. SRP012092.
Identifying regions differentially enriched in H4ac. Single-end Illu-
mina reads for shRBPJ (50 bp, 14.50 M reads after MAPQ>10 filtering and 
duplicate removal) and shRandom (75 bp, 19.70 M reads after MAPQ>10 
filtering and duplicate removal) were aligned to the NCBI36/hg18 reference 
genome with BWA version 0.5.7 (Li et al., 2009). Differentially enriched 
500-bp genome-wide regions were identified with edgeR (Robinson et al., 
2010) v2.0.3 and R v2.11.1, using edgeR’s TMM library size normalization 
to adjust for the different sequencing depths in the two libraries, and calculat-
ing B-H–corrected p-values for differential enrichment. Considering both a 
concentration versus fold change plot that we annotated with adjusted p-values 
and results from regions that we defined around transcriptional start sites 
(below), we set an adjusted p-value threshold of 0.005, a log2 fold change 
threshold of 1.0, and a log2 concentration threshold of 21.5, and generated 
a set of filtered differentially enriched regions. The concentration threshold 
rejected regions with relatively low read coverages that would be most af-
fected by variability in the ChIP-seq data.
Spatial relationship between differentially enriched regions and TSSs. 
For the above 500 bp differentially enriched regions, we determined dis-
tances between a region center and the nearest UCSC gene (Hsu et al., 2006) 
TSS. Spatial distributions were initially assessed as an empirical distribution 
function for the absolute value of distance from a differentially enriched re-
gion center to the nearest TSS (Fig. 4 F). The region in which H4ac was en-
riched was refined to 2/+1 kb by considering directional distances to a 
TSS, i.e., by considering transcript strand (Fig. 4 G). The calculations were 
done separately for regions that were differentially enriched in the shRBPJ 
versus the shRandom data, then for regions that were differentially enriched 
in the shRandom versus the shRBPJ data. Random expectations for both 
spatial distributions were generated as the mean of 20 distance calculations in 
which TSS locations on each chromosome were randomly relocated.
Identifying genes with TSS regions differentially enriched in H4ac. 
We used edgeR (Robinson et al., 2010) to identify which 2/+1 kb TSS 
regions were differentially enriched in the H4ac knockdown data. For this 
calculation, we addressed redundant TSS coordinates due to a gene having 
multiple transcripts by assigning sets of identical TSS coordinates to a single 
TSS coordinate, and merging any TSSs that were separated by <500 bp into 
a single coordinate (R script available on request). Adjusted p-values for pub-
lished RPBJ target genes were assessed in the context of a scatter plot of re-
gional read concentration versus fold change. From this, we set an adjusted 
p-value threshold of 0.005, a log2 fold change threshold of 1.0, and a log2 
concentration threshold of 16, and generated a set of 114 filtered, differen-
tially expressed TSS regions. More stringent concentration filtering was cho-
sen for TSS regions than for genome-wide bins because genome-wide bins 
were used to identify the extent of TSS regions, whereas thresholded TSS re-
gions were used to define genes that were likely regulated by RBPJ binding.
Spatial relationship between differentially expressed regions and CHIP-
seq data. 55 ENCODE (Birney et al., 2007) ChIP-seq threshold region da-
tasets were downloaded from the UCSC hg18 genome browser. Excluding 
Pol3 and TAF1 because they are not transcription factors (TFs), and using 
custom Mathematica scripts (Wolfram Research), we filtered each of the re-
maining 52 TF datasets and 1 input DNA dataset by removing records for any 
region that had a score in the lowest 10% for that TF or a length in the upper 
10% for that TF. For each filtered dataset, we calculated distances between the 
center of a filtered, genome-wide 500 bp H4ac differentially enriched region 
the cells were then washed in PBS and harvested in the presence of protease 
inhibitors. ChIP was performed as previously described (Robertson et al., 
2008). Chromatin DNA was fragmented by sonication for 10 min using the 
Sonic Dismembrator 550 (cup horn; Thermo Fisher Scientific) to produce 
chromatin fragments ranging from 100 to 800 bp. The chromatin was pre-
cleared with 40 µl of blocked Protein A/G Sepharose beads (GE Healthcare) 
at 4°C for 2 h. After centrifugation, supernatant was removed from the beads 
and transferred to fresh tubes. Each immunoprecipitation was performed 
with 100 µg (histone IPs) or 25 µg (transcription factor IPs) of precleared 
chromatin and 2.5 µg of anti-H4ac antibody (H4K5/K8/K12/K16, product 
number 06–866; EMD Millipore), 4 µl rabbit anti-histone H3 trimethyl 
lysine 4 clone MC315 (Millipore), rabbit anti-histone H3 trimethyl lysine 
9 (ab8898; Abcam), 2 µg anti–NF-B p50 antibody (H-119; Santa Cruz Bio-
technology, Inc.), 2 µg anti-c-MYC antibody (N-262; Santa Cruz Biotech-
nology, Inc.), or 4 µg rabbit IgG from (EMD Millipore), and was incubated at 
4°C for 1 h. To each immunoprecipitation reaction, 20 µl of protein A/G 
Sepharose beads were added and incubated by rotating at 4°C overnight. 
Beads were recovered by centrifugation and washed twice with ChIP wash 
buffer (20 mM Tris-HCl, pH 8.0, 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 
and 150 mM NaCl) and once with ChIP final wash buffer (20 mM Tris-HCl, 
pH 8.0, 0.1% SDS, 1% Triton X-100, 2 mM EDTA, and 500 mM NaCl). 
DNA–antibody complexes were eluted using 100 µl Elution Buffer (100 mM 
NaHCO3 and 1% SDS), and 5 µg DNase-free RNase (Roche) was added 
and incubated at 68°C for 2 h with shaking on a thermomixer to reverse the 
cross-links. The beads were pelleted by centrifugation and the supernatant 
was collected. Elution was repeated with the addition of 100 µl of Elution 
Buffer and incubation at 68°C for 5 min with shaking on a thermomixer. 
After pooling the two elutions, DNA was recovered from the eluate using the 
QIAquick PCR Purification kit (QIAGEN). The immunoprecipitated DNA 
was validated by qPCR using 0.25 µM final concentration GAPDH primers 
(Forward Part# 101221; Reverse Part # 101222 from Active Motif), HEY2-
160, HEY2 TSS (Table S4), and ZNF3 as a negative control. qPCR was set up 
on a 7900HT Fast Real-Time PCR System (Applied Biosystems) using 1 µl of 
immunoprecipitated eluate and the SYBR Green PCR Master Mix (Applied 
Biosystems). Cycling parameters were 95°C for 10 min, 40× (95°C for 10 s, 
59°C for 30 s, and 72°C for 30 s), 72°C for 5 min, 95°C for 15 s, 59°C for 
15 s, and 95°C for 15 s. Fold enrichment was calculated as 2(Ct IgG  Ct target).
RBPJ ChIP. shRandom or shRBPJ MDA-MB-231 cell lines were grown 
and processed for ChIP as described above with the following changes: chro-
matin preparation and immunoprecipitation steps were performed as de-
scribed in the SimpleChIP Enzymatic Chromatin IP kit (Cell Signaling 
Technology) except using Protein A/G agarose beads (Promega). Each im-
munoprecipitation was performed with 20 µg of precleared chromatin and 
10 µl rabbit anti-RBPSUH (Cell Signaling Technology), rabbit anti-histone 
H3 antibody, and rabbit anti-IgG (provided by kit). The immunoprecipitated 
DNA was validated by qPCR using primers for HEY2-160, HEY2 TSS 
(Table S4), and RPL30 as a negative control (provided by the kit). Fold en-
richment was calculated as 2(Ct IgG  Ct target).
acH4 ChIP library construction and sequencing analysis. Sequencing 
libraries for the acH4 ChIP were prepared as previously described (Robertson 
et al., 2007). In brief, ChIP DNA (roughly 50 ng) was run in 8% PAGE and 
the 100–300 bp fraction was excised, eluted overnight at 4°C in 300 µl of 
elution buffer (5:1, LoTE buffer [3 mM Tris-HCl, pH 7.5, 0.2 mM EDTA]-
7.5 M ammonium acetate), and purified by ethanol precipitation using 
a Spin-X Filter Tube (Thermo Fisher Scientific). Libraries were prepared using 
the Illumina single-end (SE) library construction protocol. This involved 
DNA end-repair, and phosphorylation by T4 DNA polymerase, Klenow 
DNA Polymerase, and T4 polynucleotide kinase, respectively, in a single reac-
tion and subsequent 3 A overhang generation by Klenow fragment (3 to 5 
exo minus) and ligation to Illumina SE adapters (with 5 overhangs). Adapter- 
ligated products were purified on Qiaquick spin columns (QIAGEN) and 
PCR-amplified using Phusion DNA polymerase for 10 cycles and the SE primer 
set (Illumina). The PCR product was purified using 8% PAGE gels, and DNA 
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